| Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Co.'s late-stage clinical pipeline includes two candidates for severe genetic disorders: EDSIVO (celiprolol), which is a selective adrenergic modulator and a new chemical entity for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001, which is a taste-masked, immediate release formulation of sodium phenylbutyrate, designed to treat urea cycle disorders and Maple Syrup Urine Disease. The ACER YTD return is shown above.
The YTD Return on the ACER YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACER YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACER YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.